Case Report

Virchows Archiv

, Volume 446, Issue 5, pp 546-554

First online:

Interdigitating dendritic cell tumor with breast and cervical lymph-node involvement: a case report and review of the literature

  • Ömer UluoğluAffiliated withDepartment of Pathology, Gazi University Medical School
  • , Nalan AkyürekAffiliated withDepartment of Pathology, Gazi University Medical School Email author 
  • , Aytuğ ÜnerAffiliated withDepartment of Medical Oncology, Gazi University Medical School
  • , Uğur CoşkunAffiliated withDepartment of Medical Oncology, Gazi University Medical School
  • , Ayşegul ÖzdemirAffiliated withDepartment of Radiology, Gazi University Medical School
  • , Nahide GökçoraAffiliated withDepartment of Nuclear Medicine, Gazi University Medical School

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Interdigitating dendritic cell tumor (IDCT) is an extremely rare malignancy. It occurs primarily in lymph nodes, but extranodal involvement has also been reported. A 38-year-old woman with IDCT with breast and cervical lymph-node involvement is reported in this paper. To our knowledge, this is the first case of IDCT originating from the breast. In the breast and lymph node, the tumor displayed diffuse sheets, fascicles and storiform growth pattern. It was composed of oval to spindle cells with pale to eosinophilic cytoplasm, ill-defined cell outlines, oval nuclei with vesicular chromatin and prominent eosinophilic nucleoli. Mitotic activity was three per ten high-power fields. The neoplastic cells were intermingled with small mature lymphocytes and plasma cells. Immunohistochemical studies showed that the tumor cells were strongly and diffusely positive for vimentin, CD68, S-100 protein, CD45/leukocyte common antigen and fascin and focally positive for lysozyme, alpha-1 antitrypsin and CD4. Ki-67 labeling index was 10%. The patient was treated with combined therapeutic approaches, including surgery, radiotherapy and chemotherapy. IDCT has the potential for an aggressive clinical course. However, 32 months after the initial diagnosis, the patient is still alive and being followed with a stable tumor burden.


Interdigitating dendritic cell tumor Breast Prognosis Immunohistochemistry